Eric Furfine

TL;DR: It is found that fatty acids (FAs) compete with FcRn, revealing a clash between ligand binding and recycling, and that high-affinity HSA variants have significantly increased circulating half-lives in mice and monkeys.

TL;DR: The absence of severe toxicities at the MTD, demonstration of plasma drug concentrations active in preclinical models, and clinical pharmacodynamic evidence of VEGFR-2 inhibition warrant further development of CT-322 and suggest strong potential for Adnectin-based targeted biologics.

TL;DR: Alanine-scanning mutagenesis confirmed the calculated binding energies of these β strand interactions, indicating that these nonloop residues can expand the available binding footprint.

TL;DR: The high affinity and specificity of CT-322 binding to VEGFR-2 and its anti-tumor activities establish CT- 322 as a promising anti-angiogenic therapeutic agent and suggests that Adnectins are an important new class of targeted biologics that can be developed as potential treatments for a wide variety of diseases.

TL;DR: Efficient engineering of bispecific Adnectin targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR), two transmembrane receptors that mediate proliferative and survival cell signaling in cancer, is demonstrated.